BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
Home
»
Newsletters
» BioWorld Science
BioWorld Science
Aug. 28, 2001
View Archived Issues
Old drugs may be new therapy for Creutzfeldt-Jakob and other prion diseases
Read More
Studies demonstrate antiatherosclerotic effects of lutein
Read More
Amsterdam Molecular Therapeutics steps up LPL gene therapy program
Read More
CV Therapeutics commences phase II clinical trial of CVT-3146
Read More
Nycomed Amersham Imaging and Affitech expand human antibody agreement
Read More
CA4P development program continues as planned
Read More
Pharmacopeia and Eos Biotechnology agree to merge
Read More
Helivax demonstrates safety, immunogenicity in phase Ib trial
Read More
Two centers added to 12-week study of Neotrofin in spinal cord injury
Read More
Enbrel shows positive results in phase II clinical study of psoriasis
Read More
Invitrogen to market lentiviral vectors from Cell Genesys
Read More
Aventis highlights pipeline progress for first half of 2001
Read More
Oral suspension formulation of Trileptal soon to be available in Europe
Read More
Potent, orally bioavailable FTase inhibitors discovered at Aventis
Read More
Pharmacia presents a potent MMP inhibitor at ACS meeting in Chicago
Read More
Novel cytokine production inhibitors highlighted at the ongoing ACS meeting
Read More
Demegen receives grant in support of P-113D development for cystic fibrosis infections
Read More
Selective epoxyketone inhibitors developed at Yale University
Read More
BMS patents compounds having unique dopaminergic and serotonergic activity
Read More
Potent and selective integrin inhibitors reported by Celltech
Read More
Bone-targeting compounds in the Ariad pipeline
Read More
NeuroSearch patents nACh receptor modulators
Read More
Research at Amgen leads to the discovery of new integrin antagonists
Read More